breast cancer

News

Roche gets EU okay for first HER2-low test kit

Roche has obtained a CE Mark in the EU for a companion diagnostic that can be used to identify patients with HER2-low metastatic breast cancer who may be eligible for trea

News

AZ, Daiichi Sankyo file Dato-DXd for second indication

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (

Patients

Case Study: MHRA and AstraZeneca

Agile, responsive regulation helps early breast cancer patients to benefit from a study to potentially improve survival outcomes.

News

Surprise Enhertu rejection follows NICE process change

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described

News

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan i

News

NHS England pushes BRCA testing for Jewish community

Jewish people in England are being invited to take part in a gene testing programme to identify carriers of BRCA mutations that elevate their risk of breast cancer.

Roche gets EU okay for first HER2-low test kit

AZ, Daiichi Sankyo file Dato-DXd for second indication

Case Study: MHRA and AstraZeneca

Surprise Enhertu rejection follows NICE process change

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

NHS England pushes BRCA testing for Jewish community

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

breast cancer

Editor's Picks